Le Lézard
Classified in: Health

Icahn School of Medicine at Mount Sinai Unveils BioMedical Laureates Program to Drive Diversity, Enhance Mentorship


NEW YORK, Sept. 22, 2020 /PRNewswire-PRWeb/ -- The Icahn School of Medicine at Mount Sinai today unveiled BioMedical Laureates at Mount Sinai, a program intended to increase diversity among its basic and clinical research faculty and reinforce the school's strong ethic of mentorship. BioMedical Laureates and a companion program, Junior Laureates, will both launch in January, 2021, and will each announce new Laureates annually.

"This program is among the first programs of its kind in the country that is dedicated to the enhancement of diversity among senior research scientists at an academic medical center. The program will significantly add to our existing efforts to diversify our faculty," says Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System. "A diverse medical and scientific community will drive innovation, enhance clinical care, and enrich teaching and mentorship, fulfilling the mission that drives our work. Our Laureates will bring with them a breadth of ideas and lived experiences, while lending new perspectives and raising new questions, which in turn will lead to lasting systemic change."

The program will include two components: a biomedical laureates program and a complementary junior program. The Mount Sinai BioMedical Laureate will be selected based on the candidate's scientific track record and future promise as a leader in academic medicine, and will undergo rigorous review by a committee of senior researchers from across the institution. Selected Laureates will be given a competitive startup package based on scientific and professional development needs, which includes five years of salary, support. Two BioMedical Laureates will be selected each year, one in basic science, the other in translational or clinical science.

The Junior Laureate Program seeks candidates who have completed their doctoral degree. Junior Laureates will have the opportunity to develop their own independent research program as a member of an existing research team. Upon completion of research milestones, the Junior Laureate will transition to a Mount Sinai BioMedical Laureate position and benefits package. Two Junior Laureates will be selected each year, again one in basic science, the other in translational or clinical science.

"Having experienced first-hand the barriers and challenges associated with establishing a career in science as a Black or Latina scientist, I am really delighted that Mount Sinai is putting forth this effort and investing in what is truly the future of our research workforce," says Lynne D. Richardson, MD, Professor of Emergency Medicine and of Population Health Science and Policy, System Vice Chair of Emergency Medicine, and Co-Director of the Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai.

In partnership with the Mount Sinai Office for Diversity and Inclusion and the Center for Multicultural and Community Affairs, Laureates will be mentored and guided by an advisory group of diverse leaders in science and medicine. Mentorship will form the bedrock of each program.

"Mount Sinai Laureates will be given extensive professional training and guidance as they navigate a career in academic medicine," says Eric J. Nestler, MD, PhD, Nash Family Professor of Neuroscience, Director of The Friedman Brain Institute, and Dean for Academic and Scientific Affairs. "We will do everything we can to ensure that our Laureates thrive and their research flourishes. In five years, these programs will add 20 Black and Latinx scientists to our faculty, fundamentally changing the basic and clinical research landscape at Mount Sinai. Diversity, inclusion, and equity represent the means of achieving our mission to advance biomedicine and provide compassionate and equitable care in service to our community."

Candidates interested in more information should please contact Eric J. Nestler, MD, PhD, at [email protected].

###

About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care?from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

 

SOURCE Icahn School of Medicine at Mount Sinai


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: